Amazon continues to disrupt and challenge conventional businesses with their recent acquisition of...
- J&J collaborates with Merck to launch diabetes drug in China
- Salix to co-promote first approved non-opioid for opioid withdrawal
- EBOS Group achieves Australian pharmaceutical distribution deal
- Celgene and Skyhawk initiate five-year collaboration for neurological diseases
- Kaleido ends oversubscribed funding round at $101m
EUSA Pharma to acquire Janssen Ireland’s Sylvant for $115m
EUSA Pharma has signed a definitive agreement to purchase global rights for Sylvant (siltuximab) drug from Janssen Sciences Ireland for a cash consideration of $115m.
AbbVie signs patent licensing deal with Mylan over Humira biosimilar
AbbVie has entered patent licence agreements with Mylan for the proposed biosimilar product of its Humira (adalimumab) drug.
J&J collaborates with Merck to launch diabetes drug in China
Johnson & Johnson (J&J) subsidiary Xian Janssen Pharmaceuticals has signed a deal with Germany-based Merck to introduce Janssen’s diabetes drug Invokana to the Chinese market.
Amazon set to acquire PillPack and disrupt healthcare
Amazon continues to disrupt and challenge conventional businesses with their recent acquisition of an online pharmacy, PillPack. The deal is expected to close in the second half of 2018 and is reportedly worth close to $1B.
Salix to co-promote first approved non-opioid for opioid withdrawal
Salix Pharmaceuticals’ subsidiary Valeant Pharmaceuticals has been granted exclusive rights to co-promote US WorldMed’s Lucemyra, which is the first non-opioid to be approved by the US Food and Drug Administration (FDA) to help manage abrupt opioid withdrawal. The financial terms of the deal were not disclosed in Salix’s announcement.
EBOS Group achieves Australian pharmaceutical distribution deal
Australasia-based EBOS Group has won a tender to be the exclusive third-party distributor of pharmaceutical products to more than 400 Chemist Warehouse and My Chemist stores across Australia.
Celgene and Skyhawk initiate five-year collaboration for neurological diseases
Celgene has entered into a five-year global strategic collaboration with drug discovery and development company Skyhawk Therapeutics with an upfront payment of $60m, which may be supplemented by future license fees, milestone payments and royalties.
Kaleido ends oversubscribed funding round at $101m
Microbiome startup Kaleido Biosciences has closed its oversubscribed Series C financing round at $101m. Investment came from Fidelity Management, Invus, as well as a subsidiary of Abu Dhabi Investment Company and Flagship Pioneering, Kaleido’s founder.
Deerfield buys AlivaMab Mouse technology developer Ablexis
Investment management firm Deerfield has acquired Ablexis, a company that has developed AlivaMab Mouse technology, which is a transgenic mouse platform for human antibody drug discovery.
Are US pharma companies immune to US–Canada trade wars?
The escalating trade war between the US and Canada could be a disaster for US pharma companies as they face the threat of expropriation of intellectual property from the Canadian government.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.